TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24373390

Group type: EXPERIMENTAL
Intervention: Financial incentives (five types including reward vouchers of differing values, charity donation, participation in a lottery, choices between a lottery and a voucher, and including vouchers of differing values in the test kit)
Number of subjects: 2988

Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 2988
Study: 21702324

Group type: EXPERIMENTAL
Intervention: Experimental stannous-containing sodium fluoride dentifrice (1450 ppm fluoride)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Positive control dentifrice containing 8% arginine, calcium carbonate, and 1450 ppm fluoride as sodium monofluorophosphate
Number of subjects: 81
Study: 16098233

Group type: EXPERIMENTAL
Intervention: HLA-DRPhe47
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Anti-HLA-DR antibody
Number of subjects: 160

Group type: COMPARATOR
Intervention: Anti-HLA-DP antibody
Number of subjects: 160

Group type: COMPARATOR
Intervention: Anti-HLA-DQ antibody
Number of subjects: 160

Group type: COMPARATOR
Intervention: HLA-DPGlu69
Number of subjects: 160
Study: 11941551

Group type: EXPERIMENTAL
Intervention: Atovaquone plus pyrimethamine (1500 mg orally twice daily + 75 mg per day after a 200‐mg loading dose)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Atovaquone plus sulfadiazine (1500 mg orally twice daily + 1500 mg 4 times daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Maintenance phase of atovaquone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Atovaquone-containing regimens
Number of subjects: 39
Study: 9861117

Group type: EXPERIMENTAL
Intervention: Extradural 0.25% bupivacaine 4‐7 ml h‐1 and morphine 0.16‐0.28 ml h‐1
Number of subjects: 31

Group type: COMPARATOR
Intervention: Extradural saline and conventional analgesics
Number of subjects: 31
Study: 7611794

Group type: EXPERIMENTAL
Intervention: Cyclosporine 3 mg/kg per day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cyclosporine 1.5 mg/kg per day
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 2229765

Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 78

Group type: COMPARATOR
Intervention: New catheter
Number of subjects: 78
Study: 345174

Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg three times daily for three consecutive days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (identical pills taken according to the same schedule)
Number of subjects: 18
Study: 31869292

Group type: EXPERIMENTAL
Intervention: Appropriate antimicrobial and surgical interventions for IDU-associated infections
Number of subjects: 0
Study: 29023179

Group type: EXPERIMENTAL
Intervention: Autologous PRP treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Basal group (no treatment)
Number of subjects: 20
Study: 26502012

Group type: EXPERIMENTAL
Intervention: Long-term daily azithromycin therapy
Number of subjects: 47
Study: 26066644

Group type: EXPERIMENTAL
Intervention: Olmesartan + Calcium Channel Blocker (CCB)
Number of subjects: 4876

Group type: COMPARATOR
Intervention: Olmesartan + Diuretic
Number of subjects: 4876

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 4876
Study: 23017618

Group type: EXPERIMENTAL
Intervention: Bupropion 150mg twice daily for four weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bupropion and Placebo
Number of subjects: 55
Study: 20581657

Group type: EXPERIMENTAL
Intervention: Edotecarin (J-107088) combined with infusional 5-fluorouracil (5-FU) and leucovorin (LV)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Edotecarin (J-107088)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Edotecarin (J-107088) combined with infusional 5-FU/LV
Number of subjects: 14
Study: 17882235

Group type: EXPERIMENTAL
Intervention: Bright light therapy for 4 weeks
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Natural summer remission
Number of subjects: 73
Study: 16416134

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 50 mg folinic acid and gradually escalated 5-fluorouracil (350-500 mg/m2, days 1-5)
Number of subjects: 93

Group type: COMPARATOR
Intervention: No adjuvant chemotherapy (control group)
Number of subjects: 93
Study: 14667119

Group type: EXPERIMENTAL
Intervention: Retrograde puncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antegrade puncture
Number of subjects: 100
Study: 11064976

Group type: EXPERIMENTAL
Intervention: Preoperative indwelling bladder catheter
Number of subjects: 652

Group type: COMPARATOR
Intervention: Postoperative catheterization as necessary
Number of subjects: 652
Study: 8823257

Group type: EXPERIMENTAL
Intervention: HBI 10.0 Gy (37 patients)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: HBI 12.5 Gy (23 patients)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: HBI 15.0 Gy (18 patients)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: HBI 17.5 Gy (40 patients)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: HBI 20.0 Gy (26 patients)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 144

Group type: COMPARATOR
Intervention: Fractionated HBI vs. single high-dose HBI
Number of subjects: 144
Study: 1595920

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg bolus injection, followed by a continuous infusion at 200 micrograms.kg‐1.min‐1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Thiopental (4 mg/kg bolus injection, followed by continuous infusion at 200 micrograms.kg‐1.min‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propofol (50 and 100 micrograms.kg‐1.min‐1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 36
Study: 6205614

Group type: EXPERIMENTAL
Intervention: N‐(3,4‐dimethoxycinnamoyl) anthranilic acid (N‐5')
Number of subjects: 302

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Inactive placebo
Number of subjects: 302
Study: 31847913

Group type: EXPERIMENTAL
Intervention: Community mobilisation through groups and individual volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Support services, community group, and volunteer activities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support services only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community mobilisation activities
Number of subjects: 0
Study: 29907198

Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing every other day
Number of subjects: 325

Group type: COMPARATOR
Intervention: Daily soap and water bathing
Number of subjects: 325
Study: 27750737

Group type: EXPERIMENTAL
Intervention: HDCIS coding strategy
Number of subjects: 22

Group type: COMPARATOR
Intervention: FSP coding strategy
Number of subjects: 22
Study: 24870737

Group type: EXPERIMENTAL
Intervention: Combination group (pemetrexed + bevacizumab)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Pemetrexed group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 22401514

Group type: EXPERIMENTAL
Intervention: Gun cabinet installation (early group)
Number of subjects: 0
Study: 20116704

Group type: EXPERIMENTAL
Intervention: Ultrasound bone surgery tools
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rotary instruments
Number of subjects: 26
Study: 18589123

Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (MPS) - Group A (n = 21)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (MPS) - Group B (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mycophenolate sodium (MPS) - Cohorts A plus B (n = 40)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous mycophenolate mofetil (MMF) - Control group (n = 19)
Number of subjects: 40
Study: 16091873

Group type: EXPERIMENTAL
Intervention: Sporadic asthma
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Intermittent asthma
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Persistent asthma
Number of subjects: 161

Group type: COMPARATOR
Intervention: No recent asthma
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Persistent asthma with low FEV1%
Number of subjects: 161
Study: 12432327

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) for uterine distension
Number of subjects: 189

Group type: COMPARATOR
Intervention: Physiological solution for uterine distension
Number of subjects: 189
Study: 10519591

Group type: EXPERIMENTAL
Intervention: Exotropia patients
Number of subjects: 206

Group type: COMPARATOR
Intervention: Esotropia patients
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Exotropia patients with constant strabismus
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Smaller angles of exotropia or esotropia
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Systemic disorders
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: All patients referred for evaluation of strabismus
Number of subjects: 206
Study: 7488474

Group type: EXPERIMENTAL
Intervention: Thoracic extradural analgesia with bupivacaine and sufentanil 20 micrograms kg‐1
Number of subjects: 9

Group type: COMPARATOR
Intervention: General anaesthesia alone
Number of subjects: 9
Study: 2037712

Group type: COMPARATOR
Intervention: CMT 1.5 g orally every 12 hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CMT plus sucralfate 1 g orally every 6 hours
Number of subjects: 12
Study: 6459363

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 163

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Sucralfate (follow-up of 2,298 patients)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Sucralfate (literature review of 2,306 patients)
Number of subjects: 163
Study: 31763984

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of allogeneic cardiosphere-derived cells (CDCs) - four escalating doses (37.5-75 million cells)
Number of subjects: 14
Study: 31443220

Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg/b.m. (CAF-9)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Caffeine 11 mg/kg/b.m. (CAF-11)
Number of subjects: 16
Study: 27866501

Group type: EXPERIMENTAL
Intervention: Learning to Read in a Healing Classroom (LRHC) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (waitlist)
Number of subjects: 0
Study: 25889150

Group type: EXPERIMENTAL
Intervention: Artemisinin-naphthoquine (artemisinin-NQ)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AM-LM)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 176
Study: 24071915

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 55
Study: 21229259

Group type: EXPERIMENTAL
Intervention: 5-RM squat
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (no squat)
Number of subjects: 11
Study: 19092106

Group type: EXPERIMENTAL
Intervention: Memantine (30 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18042082

Group type: EXPERIMENTAL
Intervention: Insulin glargine pre-bed with soluble morning insulin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Insulin glargine pre-bed with soluble + NPH morning insulin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Insulin glargine pre-bed with aspart + NPH morning insulin
Number of subjects: 17

Group type: COMPARATOR
Intervention: NPH pre-bed during run-in period
Number of subjects: 17
Study: 14982565

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg before surgery, followed by 600 mg at 8, 16, and 24 hours postoperatively
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gabapentin group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 80
Study: 11678974

Group type: EXPERIMENTAL
Intervention: Combination treatment (metformin + glimepiride)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Glimepiride monotherapy
Number of subjects: 372

Group type: COMPARATOR
Intervention: Metformin monotherapy
Number of subjects: 372
Study: 9879725

Group type: EXPERIMENTAL
Intervention: PACAP (0.01‐10 pmol kg(‐1) min(‐1))
Number of subjects: 8
Study: 8036292

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms once daily in the morning
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms once daily in the evening
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms twice daily
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 3055745

Group type: EXPERIMENTAL
Intervention: Mobilisin ointment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Iontophoresis alone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31351869

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day, days 1-21) and cetuximab (400 mg/m2 on cycle one, day 1, then 250 mg/m2 once per week) in group 1 (platinum-resistant)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day, days 1-21) and cetuximab (400 mg/m2 on cycle one, day 1, then 250 mg/m2 once per week) in group 2 (cetuximab-resistant)
Number of subjects: 62
Study: 28952897

Group type: EXPERIMENTAL
Intervention: SCC+VT (standard OTP clinical care plus varenicline)
Number of subjects: 7

Group type: COMPARATOR
Intervention: SCC (standard OTP clinical care)
Number of subjects: 7
Study: 26847368

Group type: EXPERIMENTAL
Intervention: Left side placement
Number of subjects: 87

Group type: COMPARATOR
Intervention: Back placement
Number of subjects: 87
Study: 22965967

Group type: COMPARATOR
Intervention: Common standard arm with cytarabine- and anthracycline-based standard-dose remission induction and high-dose consolidation courses
Number of subjects: 2995

Group type: COMPARATOR
Intervention: Common standard arm
Number of subjects: 2995
Study: 20122356

Group type: EXPERIMENTAL
Intervention: Electrical foot stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression
Number of subjects: 40
Study: 17847604

Group type: EXPERIMENTAL
Intervention: Ontology for meta-analysis
Number of subjects: 0
Study: 16162038

Group type: EXPERIMENTAL
Intervention: Personalized Instruction (PI)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Self-Study (SS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed Training (DT)
Number of subjects: 20
Study: 11029607

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 9243149

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (100 mg 2 h infusion) followed by heparin (20 IU.kg‐1.h‐1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Streptokinase (100,000 IU.h‐1 12 h infusion after an initial bolus of 250,000 IU over 15 min) followed by heparin (10 IU.kg‐1.h‐1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both interventions (Recombinant tissue plasminogen activator and Streptokinase)
Number of subjects: 50
Study: 8281592

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: 16 mg ondansetron
Number of subjects: 923

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 923

Group type: COMPARATOR
Intervention: 1 mg ondansetron
Number of subjects: 923
Study: 3329420

Group type: EXPERIMENTAL
Intervention: Early discharge (EG)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Regular postpartum care in hospital (CG)
Number of subjects: 164
Study: 2828289

Group type: EXPERIMENTAL
Intervention: 37.5 Gy in 15 fractions over 3 weeks (HD)
Number of subjects: 168

Group type: COMPARATOR
Intervention: 25 Gy in ten fractions over 2 weeks (SD)
Number of subjects: 168
Study: 31884309

Group type: EXPERIMENTAL
Intervention: Auto-titrating CPAP
Number of subjects: 196

Group type: COMPARATOR
Intervention: No-CPAP
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Both CPAP and no-CPAP
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: CPAP adherence
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Number of subjects: 196
Study: 31028597

Group type: EXPERIMENTAL
Intervention: Chain community pharmacies
Number of subjects: 12
Study: 28038377

Group type: EXPERIMENTAL
Intervention: Brief Interpersonal Psychotherapy (brief‐IPT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 42
Study: 26403472

Group type: EXPERIMENTAL
Intervention: Probiotic chewing tablets (ProBiora3), one tablet per day for one year
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo chewing tablets (identical tablets without bacteria)
Number of subjects: 138
Study: 23036096

Group type: EXPERIMENTAL
Intervention: Standard-dose stavudine (30-40 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose stavudine (20-30 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tenofovir (TDF, 300 mg)
Number of subjects: 60
Study: 21740798

Group type: EXPERIMENTAL
Intervention: 20% human albumin (HA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 90
Study: 19364890

Group type: EXPERIMENTAL
Intervention: Virtual visits (desktop videoconferencing)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Face‐to‐face visits
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Virtual visits vs Face‐to‐face visits
Number of subjects: 175
Study: 16707070

Group type: EXPERIMENTAL
Intervention: Surgery (Group 3)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Injection sclerotherapy (compared with conservative treatment)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Surgery (compared with sclerotherapy)
Number of subjects: 1009
Study: 15086644

Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once a day (n=424)
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg once a day (n=410)
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Placebo (n=208)
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once a day
Number of subjects: 1042

Group type: EXPERIMENTAL
Intervention: Nabumetone 1,000 mg once a day
Number of subjects: 1042

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1042
Study: 11710708

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment with folic or folinic acid supplementation
Number of subjects: 236

Group type: COMPARATOR
Intervention: Methotrexate treatment without folic or folinic acid supplementation
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Presence of C677T mutation
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Efficacy parameters of MTX treatment
Number of subjects: 236
Study: 9385480

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 800 mg/d
Number of subjects: 72

Group type: COMPARATOR
Intervention: Zidovudine (ZDV) 500 mg/d
Number of subjects: 72
Study: 7961231

Group type: EXPERIMENTAL
Intervention: Acute altitude exposure (4,300 m)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Chronic altitude exposure (4,300 m)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Post 1 (return to sea level after 20 days at altitude)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Post 2 (return to sea level after 20 days at altitude)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Maximal voluntary contractions (MVC) of rested muscle
Number of subjects: 8
Study: 3300312

Group type: EXPERIMENTAL
Intervention: Oral norfloxacin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Parenteral agents
Number of subjects: 94
Study: 31342604

Group type: EXPERIMENTAL
Intervention: Î²-Elemene
Number of subjects: 0
Study: 28634056

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT) administered in 3 sessions with an energy flux density of 0.2, 0.4, and 0.6 mJ/mm2 (low, moderate, high intensity)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Predictive factors from logistic regression model
Number of subjects: 278
Study: 25926415

Group type: EXPERIMENTAL
Intervention: Protein supplementation (27.5 g of protein, 15 g of carbohydrate, and 0.1 g of fat every night before sleep)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (noncaloric)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Protein supplementation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22569992

Group type: EXPERIMENTAL
Intervention: High hENT1 expression
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: High RRM2 expression
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: High ERCC1 expression
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy (subset analysis, n = 74) with high RRM2 and ERCC1 expression
Number of subjects: 95
Study: 21198991

Group type: EXPERIMENTAL
Intervention: Revised Geneva score (RGS) - low probability group
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Revised Geneva score (RGS) - intermediate probability group
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Revised Geneva score (RGS) - high probability group
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Revised Geneva score (RGS) - all probability groups
Number of subjects: 1334
Study: 18382378

Group type: EXPERIMENTAL
Intervention: Single-fit mode (SF-mode)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multiple-fit mode (MF-mode)
Number of subjects: 40
Study: 16480404

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg at bedtime
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 14607557

Group type: EXPERIMENTAL
Intervention: Highly purified hMG
Number of subjects: 22

Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 22
Study: 10798765

Group type: EXPERIMENTAL
Intervention: LO-CD2a/BTI-322 mAb
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 9068738

Group type: EXPERIMENTAL
Intervention: Itraconazole pulse therapy, 400 mg daily 1 week per month for 3 months
Number of subjects: 129

Group type: COMPARATOR
Intervention: Continuous treatment with itraconazole, 200 mg daily for 3 months
Number of subjects: 129